<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2014-09-10">September 10, 2014</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Lisa</forename><surname>Bodei</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Nuclear Medicine</orgName>
								<orgName type="institution">European Institute of Oncology</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anders</forename><surname>Sundin</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Radiology</orgName>
								<orgName type="department" key="dep2">Section for Molecular Imaging</orgName>
								<orgName type="institution">Uppsala University Hospital</orgName>
								<address>
									<settlement>Uppsala</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Kidd</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Gastroenterological Surgery</orgName>
								<orgName type="institution">Yale University School of Medicine</orgName>
								<address>
									<settlement>New Haven</settlement>
									<region>Conn</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vikas</forename><surname>Prasad</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Nuclear Medicine</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Irvin</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
							<email>imodlin@optonline.net</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Gastroenterological Surgery</orgName>
								<orgName type="institution">Yale University School of Medicine</orgName>
								<address>
									<settlement>New Haven</settlement>
									<region>Conn</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bodei</forename><forename type="middle">/</forename><surname>Sundin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Kidd</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Prasad</surname></persName>
						</author>
						<author>
							<persName><forename type="first">/</forename><surname>Modlin</surname></persName>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">Yale University</orgName>
								<address>
									<addrLine>333 Cedar Street</addrLine>
									<postBox>PO Box 208062</postBox>
									<postCode>06510</postCode>
									<settlement>New Haven</settlement>
									<region>CT</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2014-09-10">September 10, 2014</date>
						</imprint>
					</monogr>
					<idno type="MD5">6522AFACC25DFD691F9FBD115DD1184A</idno>
					<idno type="DOI">10.1159/000367850</idno>
					<note type="submission">Received: June 10, 2014 Accepted after revision: August 23, 2014</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:43+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Neuroendocrine tumors</term>
					<term>Imaging</term>
					<term>Computed tomography</term>
					<term>Magnetic resonance imaging</term>
					<term>Scintigraphy</term>
					<term>Positron emission tomography</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>captures the global status of an individual's tumor and encompasses a multidimensional characterization of tumor location, metabolic performance and target identification.</s><s>To date, advances in imagery have focused on increasing resolution, discrimination and functional characterization.</s><s>In the future, the fusion of imagery with the parallel analysis of biological and genomic information has the potential to considerably amplify diagnosis.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Neuroendocrine tumors (NETs) represent a considerable diagnostic challenge as their clinical presentation is protean, nonspecific and usually late, often when hepatic metastases are already evident <ref type="bibr" target="#b0">[1]</ref> .</s><s>In their diagnostic workup, two critical issues are present: firstly, the need to identify tumor presence and, secondly, to define the primary location and assess regional and distant metastases.</s><s>Plasma biomarkers and imaging have been used to define these areas.</s><s>This includes molecular imaging techniques to acquire information on the tumor's somatostatin receptor (SSR) expression [SSR scintigraphy (SRS)] and metabolic status [ 18 fluorodeoxyglucose-positron emission tomography ( 18 FDG-PET)] and histopathological examination of tumor biopsies, including immunohistochemistry, providing further information, 2 for example, on its proliferative activity (Ki67).</s><s>Current biomarkers such as chromogranin-A (CgA) and 5-hydroxyindoleacetic acid (5-HIAA) are, however, generally accepted as suboptimal in terms of sensitivity and specificity <ref type="bibr" target="#b1">[2]</ref> .</s><s>The recent demonstration of specific NET transcripts in whole blood suggests that this strategy may enable early diagnosis and detection of lesions and may provide a basis for prognostic determination and therapeutic recommendation <ref type="bibr" target="#b2">[3]</ref> .</s><s>The currently evolving research area denoted 'precision medicine', by which, for example, correlations between genomics and image findings may be established, is resource demanding but holds great potential.</s></p><p><s>Imaging plays a pivotal role in diagnosis, staging, treatment selection and follow-up of NETs ( fig. <ref type="figure">1</ref> ).</s><s>Current diagnostic methods include morphologic modalities such as computed tomography (CT), magnetic resonance imaging (MRI), transabdominal ultrasound (US), endoscopic US (EUS) and intraoperative US (IOUS).</s><s>Nuclear medicine imaging or molecular imaging consists of scintigraphy including single photon emission computed tomography (SPECT) with 111 In-pentetreotide or, more recently, PET with 68 Ga-labeled somatostatin analogs (SSA), 18 F-DOPA and 11 C-5-HTP <ref type="bibr" target="#b0">[1]</ref> .</s><s>Because of the large variability between NETs in, for instance, proliferation rate (Ki67) and SSR subtype profile, no modality alone is entirely effective and, overall, these exhibit a sensitivity and specificity of ∼ 80-90% <ref type="bibr" target="#b3">[4]</ref> ( fig. <ref type="figure" target="#fig_1">2</ref> ).</s><s>A combination of anatomic and functional techniques is routinely performed to optimize sensitivity and specificity and thereby maximize the acquisition of clinically relevant information <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> .</s><s>This has been facilitated by the development of current hybrid scanners (SPECT/CT and PET/CT), whereby functional image findings may be directly correlated to morphology and vice versa.</s><s>In disseminated disease, the tumor's SSR status is generally assessed by 111 In-pentetreotide scintigraphy or 68 Ga-SSA-PET/CT in order to also evaluate the patient's eligibility for peptide receptor radionuclide therapy (PRRT).</s><s>This assessment was previously a prerequisite, also before starting systemic treatment with unlabeled SSA, but this routine has during the last few years been questioned.</s></p><p><s>The major unmet need in NET imaging is, however, the development of more inclusive criteria for therapy monitoring that apply to slow-growing tumors and allow the validation of the more recent functional techniques (MRI and PET) as well as integrate biologic and metabolic information ( table 1 ) <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b6">7]</ref> .</s><s>This article assesses the strengths and limitations of current imaging approaches for NETs and describes the future perspectives using a SWOT analysis structure.</s><s>NET Molecular imaging 111 In-OCT 68 Ga-PET 18 F-DOPA 11 C-5-HTP 18 FDG Gene transcripts CgA Fig. <ref type="figure">1</ref>.</s><s>Venn diagram of modalities involved in the identification of a NET. 111 In-OCT = 111 In-pentetreotide scintigraphy; 68 Ga-PET = PET with 68 Ga-DOTA-peptides; 18 F-DOPA = 18 F-dihydroxyphenylalanine; 11 C-5-HTP = 11 C-5-hydroxy-L -tryptophan; FNA = fine-needle aspiration; FNB = fine-needle biopsy; CTC = circulating tumor cells.</s><s>SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> CT/MRI: surgery <ref type="bibr" target="#b0">[1]</ref> SRI <ref type="bibr" target="#b47">[47,</ref><ref type="bibr" target="#b57">57]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> Pancreas (nonfunctional)</s></p><p><s>EUS <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b7">8]</ref> SRI <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b117">115,</ref><ref type="bibr" target="#b119">117]</ref> CT/MRI <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b118">116]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> 11 C-5-HTP <ref type="bibr" target="#b26">[26]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> 11 C-5-HTP <ref type="bibr" target="#b26">[26]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> CT/MRI: surgery <ref type="bibr" target="#b0">[1]</ref> SRI <ref type="bibr" target="#b47">[47,</ref><ref type="bibr" target="#b57">57]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> Duodenum SRI <ref type="bibr" target="#b21">[21,</ref><ref type="bibr">114,</ref><ref type="bibr" target="#b117">115]</ref> EUS <ref type="bibr" target="#b0">[1]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> 11 C-5-HTP <ref type="bibr" target="#b26">[26]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> 11 C-5-HTP <ref type="bibr" target="#b26">[26]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> CT/MRI: surgery <ref type="bibr" target="#b0">[1]</ref> SRI <ref type="bibr" target="#b47">[47,</ref><ref type="bibr" target="#b57">57]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> Small bowel SRI <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b119">[117]</ref><ref type="bibr" target="#b120">[118]</ref><ref type="bibr" target="#b121">[119]</ref> video-capsule DB enteroscopy <ref type="bibr" target="#b122">[120]</ref> CT <ref type="bibr" target="#b7">[8]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> 18 F-DOPA <ref type="bibr" target="#b58">[58]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> 18 F-DOPA <ref type="bibr" target="#b58">[58]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> CT/MRI: surgery <ref type="bibr" target="#b0">[1]</ref> SRI <ref type="bibr" target="#b119">[117]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> Gastric EUS <ref type="bibr" target="#b7">[8]</ref> SRI <ref type="bibr" target="#b123">[121]</ref> CT <ref type="bibr" target="#b123">[121]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> Endoscopy: resection <ref type="bibr" target="#b123">[121]</ref> Colon EUS <ref type="bibr" target="#b7">[8]</ref> SRI <ref type="bibr" target="#b123">[121]</ref> CT <ref type="bibr" target="#b123">[121]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> Endoscopy: resection <ref type="bibr" target="#b123">[121]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> CT: surgery <ref type="bibr" target="#b0">[1]</ref> SRI <ref type="bibr" target="#b57">[57]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> Rectum EUS <ref type="bibr" target="#b7">[8]</ref> SRI <ref type="bibr" target="#b123">[121]</ref> CT/MRI SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> CT: surgery <ref type="bibr" target="#b0">[1]</ref> Endoscopy: resection <ref type="bibr" target="#b0">[1]</ref> SRI <ref type="bibr" target="#b57">[57]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> Bronchial Bronchia Bronchoscopy <ref type="bibr" target="#b122">[120]</ref> SRI <ref type="bibr" target="#b124">[122]</ref> SRI <ref type="bibr" target="#b125">[123]</ref> CT <ref type="bibr" target="#b125">[123]</ref> FDG <ref type="bibr" target="#b126">[124]</ref> SRI <ref type="bibr" target="#b125">[123]</ref> CT <ref type="bibr" target="#b125">[123]</ref> FDG <ref type="bibr" target="#b126">[124]</ref> Bronchoscopy: resection <ref type="bibr" target="#b122">[120]</ref> CT (MRI): surgery <ref type="bibr" target="#b125">[123]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> SRI <ref type="bibr" target="#b57">[57]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> Unknown Unknown SRI <ref type="bibr" target="#b127">[125]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> SRI + CT/MRI <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> SRI: SSA, PRRT <ref type="bibr" target="#b48">[48]</ref> CT: surgery, locally directed ablative therapies <ref type="bibr" target="#b123">[121]</ref> SRI <ref type="bibr" target="#b57">[57]</ref> FDG <ref type="bibr" target="#b29">[29]</ref> GEP = Gastroenteropancreatic; SRI = somatostatin receptor imaging with either 111 In-pentetreotide or PET/CT with 68 Ga-DOTA-SSA; DB enteroscopy = double-balloon enteroscopy.</s><s>a Except for insulinoma.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Techniques</head><p><s>(1) US: Transabdominal US is often the first technique utilized for NET imaging.</s><s>This is simply based upon its noninvasiveness and utility.</s><s>Its efficacy is, however, low.</s><s>US allows for easy guidance of the biopsy needle for fineneedle aspiration cytology or core biopsy for histopathological examination.</s><s>Improved techniques, including contrast-enhanced US (CEUS), EUS and IOUS have allowed for an increase in sensitivity.</s></p><p><s>(2) CT/MRI: Primary NETs are usually identified using conventional imaging with intravenously contrastenhanced CT and MRI which are also the principal methods used for the detection of the primary tumor, describing its local extent, staging of locoregional and distant metastases, as well as for the assessment of therapeutic response.</s><s>Contemporary CT utilizes multidetector (MDCT) scanners, while MRI employs a field strength of at least 1.5 T and currently includes many signal sequences to increase tissue contrast and facilitate tissue characterization.</s><s>Unless contraindicated, for instance because of impaired kidney function, both CT and MRI of the liver and pancreas should be performed as multiphasic studies before and during intravenous contrast enhancement in the late arterial (portal venous inflow) and venous (portal-venous) phases <ref type="bibr" target="#b7">[8]</ref> .</s><s>Since neuroendocrine lesions and their metastases are usually hypervascular, they enhance in the late arterial phase after contrast medium injection on CT and MRI.</s><s>The variations in this aspect are large and it is fairly common also with hypovascular metastases that are best delineated in the venous contrast enhancement phase.</s><s>Occasionally, the patient may harbor both hypervascular and hypovascular liver metastases.</s><s>The sensitivity for pancreatic NETs ranges from 69 to 94% for CT, 74 to 94% for MRI and is &gt;80% for EUS coupled with biopsy <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref> .</s><s>The sensitivity for locating a primary small intestine NET is 100% for CT enteroclysis and 86-94% for MRI <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> .</s></p><p><s>(3) Nuclear medicine imaging or molecular imaging: These techniques provide information for establishing the SSR status ( 111 In-pentetreotide), metabolic activity ( 18 FDG) and specific amine or peptide regulatory profile (e.g. 18</s><s>F-DOPA).</s><s>In addition, they generally provide further details in respect of the extent of disease and thereby facilitate more accurate staging and precise therapy.</s></p><p><s>(a) The radiolabeled SSA 111 In-pentetreotide is the most commonly used agent for SRS.</s><s>Examination comprises two-dimensional planar imaging and three-dimensional SPECT at 4, 24 and optionally at 48 h after injection according to recommended protocols <ref type="bibr" target="#b16">[17]</ref> .</s></p><p><s>With the increasing use of SPECT/CT, allowing for anatomical correlation of the SPECT findings, the need for the 4-and 48-hour examinations is, however, generally low.</s><s>The sensitivity of 111 In-pentetreotide scintigraphy has been well documented and is generally &gt;75% for gastroenteropancreatic and bronchial tumors <ref type="bibr" target="#b17">[18]</ref> .</s><s>Since 2000, the approach to the molecular imaging of NETs has been revolutionized by the introduction of PET with the 68 Ga-labeled octreotide derivatives DOTATOC, DOTATATE and DOTANOC ( 68 Ga-SSA-PET/CT) <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref> .</s><s>The overall sensitivity of 68 Ga-SSA-PET/CT for NETs is &gt;90%, while the specificity ranges from 92 to 98% <ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref><ref type="bibr" target="#b23">[23]</ref> .</s><s>Recently, 64 Cu-labeled SSA has also been tested for PET/CT of NETs <ref type="bibr" target="#b24">[24]</ref> .</s></p><p><s>(b) Alternative PET tracers: These include 18 F-DOPA, which measures neuroendocrine metabolism.</s><s>This is a substrate utilized in the catecholamine synthesis pathway and is stored in the secretory granules <ref type="bibr" target="#b25">[25]</ref> .</s><s>In research centers, 11 C-5-HTP, a serotonin precursor, which is the substrate for aromatic L -aminoacid decarboxylase, is also utilized <ref type="bibr" target="#b26">[26]</ref> . 18</s><s>FDG-PET is usually not considered a primary diagnostic tool in well-differentiated NETs because of its low sensitivity. 18</s><s>FDG PET may instead be considered for imaging of high G2 NETs with Ki67 &gt;15-20% for which SRS and 68 Ga-SSA-PET/CT may be unreliable <ref type="bibr" target="#b27">[27]</ref> . 18</s><s>FDG-PET is generally recommended for neuroendocrine cancer G3 tumors, although it has been reported as positive in 57% of G1 and 66% of G2 NETs <ref type="bibr" target="#b28">[28]</ref> .</s><s>In addition, the increased glucose metabolism, expressed as standardized uptake value (SUV), can provide predictive information in terms of overall survival and progressionfree survival (PFS) <ref type="bibr" target="#b29">[29]</ref> .</s><s>In particular, NETs that exhibited increased metabolic activity had a significantly lower disease control rate (100 vs. 76%) and PFS (32 vs. 20 months) after PRRT compared to 18 FDG-negative tumors <ref type="bibr" target="#b28">[28]</ref> .</s><s>Recent study has shown the possibility of a three-tier metabolic grading system based on the tumorto-background ratio of uptake of FDG as an independent prognostic marker <ref type="bibr" target="#b30">[30]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Technique Strengths</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Morphologic Imaging</head><p><s>Anatomic techniques are the primary imaging modalities used in the initial phase of the diagnostic workup to detect primary tumors, delineate the extent of metastatic disease, determine therapeutic strategy (particularly the margins of operability) and assess the therapeutic response ( table 2 a).   1</s><s>In-pentetreotide 68 Ga-peptides 18 F-DOPA 11 C-5-HTP 18 FDG Technical points</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuroendocrine Tumor Imaging</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Whole-body technique</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Whole-body technique</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Whole-body technique</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Whole-body technique</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Whole-body technique</head><p><s>Multiplanar imaging High spatial resolution (4-6 mm) Multidetector Computed Tomography MDCT is the standard morphologic modality for NET imaging due to its high spatial resolution, generally &lt;1 mm with recent MDCT scanners <ref type="bibr">[31]</ref> .</s><s>MDCT can localize the primary tumor, assess the extent of disease, characterize the architectural relationships with the surrounding structures and be used to reassess the disease following treatments <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref> .</s></p><p><s>The multiplanarity of this technique (transaxial, coronal, sagittal and curved planes can be reconstructed) and the three-dimensional maximum intensity projection and volume rendering techniques, which delineate the organ and vascular anatomy in 3D, improve accuracy and image interpretation <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b35">35]</ref> .</s><s>MDCT is reproducible and allows for comparison between baseline and follow-up images, irrespective of the body habitus and extent of disease.</s><s>CT is the method of choice to guide the biopsy of thoracic lesions.</s></p><p><s>Magnetic Resonance Imaging MRI has the advantage of a fairly high spatial resolution (2-4 mm), which is amplified by examination at a higher field strength in a 3-tesla scanner <ref type="bibr" target="#b36">[36]</ref> .</s><s>Optionally, the higher field strength may instead be utilized to shorten the acquisition time.</s><s>The better soft-tissue contrast of MRI, as compared to CT, is particularly useful to detect liver metastases for which MRI represents the most sensitive technique <ref type="bibr" target="#b37">[37,</ref><ref type="bibr" target="#b38">38]</ref> .</s><s>The soft-tissue contrast can be further increased by the use of liver-specific and superparamagnetic contrast media <ref type="bibr" target="#b34">[34,</ref><ref type="bibr" target="#b39">39]</ref> .</s><s>Three-dimensional acquisition allows for viewing in multiple anatomical planes to enable accurate image interpretation.</s><s>In addition, the absence of radiation exposure renders MRI the technique of choice especially in the young or those with long-standing disease who require repeated assessments <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b34">34]</ref> .</s></p><p><s>MRI has similar indications as CT and, due to availability and costs as well as its optimal interobserver agreement, it is generally used as a problem-solving technique <ref type="bibr" target="#b37">[37,</ref><ref type="bibr" target="#b40">40]</ref> .</s><s>MRI is particularly advantageous in localizing primary pancreatic tumors and for staging and restaging liver lesions <ref type="bibr" target="#b37">[37]</ref> .</s><s>Moreover, cholangiopancreatic sequences (magnetic resonance cholangiopancreatography), directed at studying the involvement of the biliary and pancreatic ducts, are useful for surgical planning and should always precede resection of a pancreatic NET <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b41">41]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>US Techniques</head><p><s>US is the modality used to guide liver and other abdominal biopsies.</s><s>The absence of radiation exposure makes it a highly repeatable technique.</s><s>Despite the gen-erally low sensitivity among anatomic modalities in localizing NETs (13-27%) <ref type="bibr" target="#b42">[42,</ref><ref type="bibr" target="#b43">43]</ref> , improved techniques, including CEUS, EUS or IOUS, show better performance.</s><s>EUS is the most advantageous modality to detect pancreatic NETs, with pooled sensitivity and specificity of 87 and 98%, respectively, in a systematic review <ref type="bibr" target="#b44">[44]</ref> , and it represents a guide for fine-needle aspiration cytology or core biopsy <ref type="bibr" target="#b45">[45]</ref> .</s><s>Finally, the juxtaposition of the probe, during IOUS, facilitates the study of the liver and the pancreas <ref type="bibr" target="#b0">[1]</ref> and is generally recommended in connection with resection of liver metastases and pancreatic NETs, especially in multiple endocrine neoplasia patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular Imaging</head><p><s>Besides localization, staging and restaging of primary and metastatic tumors, molecular imaging allows for the functional characterization of lesions and the therapy selection with cold or radiolabelled SSA (PRRT).</s><s>Functional imaging has a clinical impact in terms of modification of the therapeutic strategy and of prognosis ( table 2 b).</s><s>In-Pentetreotide This is the only universally approved radiopharmaceutical for NET imaging.</s><s>A 99m Tc-labeled compound ( 99m Tc-EDDA/HYNIC-TOC) is registered in Poland and commercially available in some European countries <ref type="bibr" target="#b46">[46]</ref> .</s><s>The use of 111 In-pentetreotide to localize, stage, restage as well as provide therapeutic indications was a major advance in NET management <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b47">47,</ref><ref type="bibr" target="#b48">48</ref>] .</s><s>An optimal protocol, including three-dimensional reconstructed SPECT images and, possibly, high-resolution CT coregistration (SPECT/CT), ensures good image quality and provides useful clinical information, as a whole body technique, and accurate image interpretation <ref type="bibr" target="#b16">[17]</ref> . 111</s><s>In-pentetreotide modifies the therapeutic strategy in up to 50% of cases <ref type="bibr" target="#b47">[47,</ref><ref type="bibr" target="#b49">49,</ref><ref type="bibr" target="#b50">50]</ref> and can predict the response to cold or radiolabeled analogues <ref type="bibr" target="#b48">[48]</ref> . 68</s><s>Ga-SSA-PET/CT This provides several advantages over conventional scintigraphy.</s><s>These include the simple and economical synthesis of the radiopeptide from an on-site 68 Ge/ 68 Ga generator eluate, the single-day procedure, the possibility of semiquantification of the activity in a given region of interest as the 'SUV', the higher spatial resolution with the detection of 4-to 6-mm lesions and, finally, the better dosimetry <ref type="bibr" target="#b51">[51]</ref>  CT produces low-dose, or preferably, diagnostic contrast-enhanced scans, with an improved accuracy and image interpretation <ref type="bibr" target="#b52">[52]</ref> .</s></p><p><s>Another advantage is the possibility of labeling and imaging the same peptide used for PRRT <ref type="bibr" target="#b22">[22,</ref><ref type="bibr" target="#b53">53]</ref> . 68</s><s>Ga-SSA-PET/CT has demonstrated a higher sensitivity than metabolic tracers, such as 18 F-DOPA and 11 C-5-HTP, and is able to sensitively visualize difficult areas including bones, peritoneum, the heart or soft tissues <ref type="bibr" target="#b54">[54,</ref><ref type="bibr" target="#b55">55]</ref> .</s><s>It allows for localization, staging and restaging and provides therapeutic indications based on tumor SSR expression <ref type="bibr" target="#b21">[21,</ref><ref type="bibr" target="#b51">51,</ref><ref type="bibr" target="#b56">56]</ref> .</s><s>Moreover, it is able to modify the therapeutic management in &gt;50% <ref type="bibr" target="#b56">[56,</ref><ref type="bibr" target="#b57">57]</ref> .</s></p><p><s>PET with 18 F-DOPA This can be of value as an alternative or problem-solving tool when SSR imaging is negative or in assessing response to treatment <ref type="bibr" target="#b51">[51]</ref> .</s><s>The sensitivity of this method is higher for carcinoids given their propensity for amine metabolism <ref type="bibr" target="#b58">[58,</ref><ref type="bibr" target="#b59">59]</ref> .</s></p><p><s>PET with 11 C-5-HTP This may be an alternative or a problem-solving tool, when SSR imaging is negative.</s><s>The sensitivity is higher for pancreatic NETs, as opposed to carcinoids, because there is no intracellular saturation from endogenous serotonin <ref type="bibr" target="#b58">[58]</ref> .</s></p><p><s>PET with 18 FDG   18   FDG is able to define prognosis in well-differentiated tumors given their low glucose substrate activity <ref type="bibr" target="#b29">[29]</ref> and can, therefore, predict a response to PRRT <ref type="bibr" target="#b28">[28]</ref> .</s><s>It is the method of choice over 68 Ga-SSA-PET/CT in the identification and assessment of poorly differentiated G3 tumors, given their lower SSR expression <ref type="bibr" target="#b60">[60]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Technique Limitations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Morphologic Imaging ( table 3 a) Multidetector Computed Tomography</head><p><s>As assessment of hypervascular metastases, especially in the liver, is critically dependent upon the exact contrast enhancement phase and contrast medium dosage, additional difficulties, therefore, exist for reproducibility, which highlights the need for fully standardized guidelines and that these are implemented in the clinical routine <ref type="bibr" target="#b7">[8]</ref> .</s><s>Poorly demarcated large-volume liver disease is generally difficult to evaluate due to coalescence phenomena, which impede distinct margin recognition, thereby limiting the possibility of response assessment using RECIST.</s><s>Other limitations include the difficulty in clear identification of small lesions, especially small lymph nodes, peritoneal lesions and bone metastases.</s><s>For small lymph nodes, even when they are depicted, the conventional size criteria are of very limited value to differ benign from metastatic lesions.</s></p><p><s>An important limitation with pure morphologic techniques such as MDCT is the risk of the underestimation of therapeutic response as defined by RECIST or SWOG response criteria.</s><s>This reflects two issues, namely the latency period required for slow-growing tumors to shrink and the possibility of tumor necrosis, fibrosis or hemorrhage obscuring a decrease in tumor size <ref type="bibr" target="#b34">[34]</ref> .</s><s>A further limitation is the different response criteria that have been designated as a different volumetric 'demand' to define progression: a 40% volume increase for SWOG/WHO criteria versus a 73% volume increase for RECIST.</s><s>This discrepancy may generate misperceptions in comparisons of 'accuracy' <ref type="bibr" target="#b61">[61]</ref> .</s><s>This limitation was recently outlined in the interpretation of the differential antiproliferative efficacy of lanreotide and octreotide in gastroenteropancreatic NETs.</s><s>The discrepant results in these two different randomized trials which assessed the antiproliferative effects of lanreotide and octreotide should be regarded in view of the different definition of PFS used by each of the groups.</s><s>The bidimensional nature of the WHO assessment employed in the octreotide study implied a lower tumor burden to define progression.</s><s>This would have resulted in a shorter PFS and, therefore, a less substantial benefit for octreotide as opposed to lanreotide <ref type="bibr" target="#b62">[62]</ref> .</s><s>However, the potential impact of this variability should be reconsidered given the results of a recent retrospective analysis of PRRT data.</s><s>In this study, both SWOG and RECIST criteria provided comparable results and predicted PFS and overall survival in a similar way <ref type="bibr" target="#b63">[63]</ref> .</s></p><p><s>Finally, radiation exposure and the use of iodinated contrast media, unsuitable for subjects with renal function impairment or those at risk for allergic reactions, represent other disadvantages.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Magnetic Resonance Imaging</head><p><s>Morphologic MRI shares with CT the same limitations inherent in anatomic imaging for the assessment of response to treatment <ref type="bibr" target="#b34">[34]</ref> .</s><s>Moreover, the costs, the limited availability, the extensive patient cooperation required and the lower familiarity of the clinicians are also problematic.</s><s>Additionally, MRI is unsuitable for the study of small thoracic lesions because of the low signal-to-noise ratio in the lung, motion artifacts due to cardiac and respiratory activity and the lower spatial resolution as compared to CT <ref type="bibr" target="#b64">[64]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>US Techniques</head><p><s>The low sensitivity, the lack of reproducibility and operator dependency make abdominal US an inadequate tool for diagnosis and monitoring of therapy.</s><s>For detection and characterization of liver lesions, CEUS is an excellent tool, but evaluation of the pancreas is restricted due to the presence of overlying bowel gas and other structures that impede optimal evaluation <ref type="bibr" target="#b65">[65]</ref> .</s><s>EUS and IOUS are similarly operator-dependent and require specialized expertise.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular Imaging ( table 3 b) SSR Imaging</head><p><s>The major limitation of conventional SRS with 111 Inpentetreotide is the low spatial resolution (approximately 1.5 cm) and, therefore, lower sensitivity compared to MRI and CT <ref type="bibr" target="#b37">[37]</ref> .</s><s>On a nonhybrid camera, lacking CT fusion, the procedure requires 2 and occasionally 3 days and, like any nuclear medicine procedure, has radiation exposure.</s><s>The possibility of interference in the uptake by cold analogues and the low sensitivity for insulinomas due to their low SSR density, especially true for benign insulinomas, hamper SRS <ref type="bibr" target="#b66">[66,</ref><ref type="bibr" target="#b67">67]</ref> .</s></p><p><s>Despite the orphan drug status of 68 Ga-DOTATOC, 68 Ga-DOTATATE and 68 Ga-DOTANOC, neither of the <ref type="bibr" target="#b68">68</ref> Ga-DOTA-SSA are registered, which poses logistic difficulties.</s><s>An additional major limitation of 68 Ga-SSA-PET/CT is the lack of reproducibility due to the lack of standardization as regards the preparation, the production procedure and examination protocols.</s><s>Because of this variability and since tissue distribution of 68 Ga-DOTA-SSA is influenced by several other factors, PET measurements of SUV in tumor and normal tissues are not entirely reliable, although it has been demonstrated that SUV max at preoperative 68 Ga-DOTANOC significantly correlated with the quantitative assessment of receptor density at immunohistochemistry for SSR2 and 5 in the surgical specimens <ref type="bibr" target="#b68">[68]</ref> .</s></p><p><s>PET/CT with 18 F-DOPA Two limited-size studies report an inferior sensitivity of 18 F-DOPA compared to receptor PET <ref type="bibr" target="#b54">[54,</ref><ref type="bibr" target="#b55">55]</ref> .</s><s>This technique thus requires validation in robust series <ref type="bibr" target="#b69">[69]</ref> .</s><s>Another limitation is the lack of a therapeutic counterpart.</s></p><p><s>PET/CT with 11 C-5-HTP This modality requires an on-site cyclotron and is available only in a few specialized centers.</s><s>The lack of full validation is a major limitation.</s><s>In addition, there is no therapeutic application.</s><s>PET/CT with 18 FDG Despite some encouraging publications, the prognostic value in NETs has not been validated either in a large series or as a response to the available therapies <ref type="bibr" target="#b60">[60]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The Future</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strategies to Advance Current Techniques ( table 4 ) Morphologic Imaging</head><p><s>Currently, lesion volume comparisons are based purely on monodimensional (RECIST) or rarely bidimensional (SWOG/WHO) assessments.</s><s>Neither technique adequately delineates the actual course of the disease, given the modest volumetric changes in NETs and/ or the possible simultaneous tissue modifications due to hemorrhage, fibrosis or tumor liquefaction.</s><s>In this respect, attenuation measurement on CT, to assess the changes of Hounsfield units, may better define the posttherapeutic tissue variations.</s><s>The Choi criteria incorporate attenuation measurements on CT and add a ≥ 15% decrease of Hounsfield units to the 10% decrease in the longest lesion diameter as a parameter to indicate response <ref type="bibr" target="#b70">[70]</ref> .</s><s>These criteria, which were initially proposed for gastrointestinal stromal tumors, have also been tested for NETs <ref type="bibr" target="#b34">[34]</ref> but require further validation.</s></p><p><s>A similar problem relates to the validation of examination protocols for comparing multiphasic imaging (CT and MRI) in order to ensure staging procedures are robust and reproducible.</s><s>This is especially necessary for studies performed in different institutions which involve timing and duration of acquisition in relation to contrast medium injection, precise contrast medium dosage and contrast enhancement phase <ref type="bibr" target="#b71">[71]</ref> , and appearance of hypovascularization <ref type="bibr" target="#b72">[72]</ref> .</s><s>In order to obviate the integral problems inherent in a purely anatomical response evaluation, e.g. the variation in diameter, the integration of RECIST criteria with functional MRI parameters, such as arterial enhancement and necrosis, has been proposed.</s><s>Following embolization of liver metastases, changes in each of these parameters have independently been associated with PFS <ref type="bibr" target="#b73">[73]</ref> .</s></p><p><s>SSR imaging has been demonstrated to timely predict the response to therapies such as SSA and PRRT <ref type="bibr" target="#b56">[56,</ref><ref type="bibr">74]</ref> .</s><s>It has been proposed that a further measure that could increase the accuracy of therapy monitoring is the integration of 68 Ga-SSA-PET/CT.</s><s>This could be achieved in a similar way to the PERCIST criteria for FDG evaluation of responses to cancer therapy, where the SUV corrected for lean body mass, calculated in regions of interest of fixed diameter, is used to obtain a scale of response <ref type="bibr" target="#b76">[75]</ref> .</s><s>However, functional therapy monitoring with 68 Ga-DOTATOC by using tumor SUV changes during PRRT, as compared to baseline, has not yet produced convincing results <ref type="bibr">[74,</ref><ref type="bibr" target="#b77">76]</ref> .</s><s>This could, at least partly, be related to differences in the administered amount of peptide between studies <ref type="bibr" target="#b78">[77]</ref> and the fact that SUV does not seem to reflect SSR expression in tumors with a SUV &gt;20-25 <ref type="bibr" target="#b79">[78]</ref> .</s><s>For therapy monitoring, diagnosis of progressive disease based on the appearance of new tumors could be more easily visualized with molecular imag-ing, particularly lesions that generally are difficult to diagnose by CT, such as peritoneal lesions and bone metastases <ref type="bibr" target="#b80">[79,</ref><ref type="bibr" target="#b81">80]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional Imaging</head><p><s>In order to ensure acceptance by clinicians, 68 Ga-SSA-PET/CT needs to be developed as an efficient and reproducible molecular imaging procedure.</s><s>There are several requirements that include: the choice of peptide, type of radiopharmaceutical preparation procedure and examination protocol in order to ensure reproducibility of the technique.</s></p><p><s>None of the three peptides currently in use (-TOC, -TATE and -NOC) demonstrates a clear diagnostic superiority over the others <ref type="bibr" target="#b82">[81,</ref><ref type="bibr" target="#b83">82]</ref> .</s><s>Regarding preparation procedures, besides the European Pharmacopeia monograph on DOTATOC, the other 68 Ga-SSA preparations are syn- Validation of high-power magnetic fields (≥3 T)</s></p><p><s>Validation of scanning protocols for multphasic imaging (CT and MRI) Molecular imaging 68 Ga-SSA-PET validation (preferred peptide, peptide dose, preparation, quantification) 64 Cu-DOTA peptides 18 FDG validation 68 Ga-SSA-PET/MRI 18 F-DOPA validation for therapy monitoring Impact of 68  11 thesized according to local, nonstandardized routines.</s><s>As regards the reproducibility of the PET technique, despite some degree of uniformity offered by the EANM guidelines, current examination protocols vary in the acquisition time point in relation to tracer administration and in the amount of administered peptide.</s><s>Also pertaining to this, there are large variations between centers on the view of the optimal preparation of the patients as regards the time interval between cold SSA injection and imaging.</s><s>These factors, together with the inherent problems of PET measurements in tumors with high 68 Ga-SSA-uptake, as discussed previously <ref type="bibr" target="#b79">[78]</ref> , make SUV, the semiquantitative parameter to express uptake, less reliable.</s><s>Moreover, SUV is intrinsically variable and may fluctuate among individual PET scanners and between centers unless these are cross-calibrated.</s><s>Thus, the reproducibility of 68 Ga-SSA-PET/CT may vary with the type of preparation and its SSR subtype affinity profile, the examination time after tracer injection, scanning times (resulting in different phases of tumor uptake at the subsequent bed positions), the SSR saturation in tumors and nontumor tissues as a consequence of the injected amount of peptide and the relation to administration of cold SSA <ref type="bibr" target="#b85">[83]</ref> and after splenectomy <ref type="bibr" target="#b86">[84]</ref> .</s><s>The use of tumor-to-normal-tissue ratios, such as tumor-to-liver and tumor-to-spleen, is a means to decrease the influence of these many factors that may reduce the accuracy of SUV measurements <ref type="bibr">[74,</ref><ref type="bibr" target="#b87">85]</ref> .</s><s>Delineation of the patient's total tumor load, usually assisted by semiautomated software, has also been tested to calculate the 'total somatostatin receptor tumor volume' <ref type="bibr" target="#b79">[78]</ref> or molecular tumor volume <ref type="bibr" target="#b88">[86]</ref> .</s><s>Particularly in larger centers, treating patients with PRRT, the increasing use of 68 Ga-SSA-PET/CT has rendered SRS obsolete, and the only remaining indication for SRS is to assess the patient's eligibility for PRRT.</s><s>Therefore, an objective adaptation of the so-called 'Rotterdam scale' or 'Krenning scale' to 68 Ga-SSA-PET/CT needs to be developed to validate its predictive value.</s><s>Another important issue is a clinical validation of 18 FDG uptake as a prognostic marker for NET aggression and as a tracer to monitor NET therapy response <ref type="bibr" target="#b27">[27,</ref><ref type="bibr" target="#b28">28]</ref> .</s><s>Moreover, 18 F-DOPA should be validated and compared to 68 Ga-SSA-PET/CT in large series <ref type="bibr">[31]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Novel Techniques and Strategies</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Morphological Imaging</head><p><s>Diffusion-Weighted MRI Diffusion-Weighted MRI (DWI) has been reported to be a sensitive modality to detect and characterize liver me-tastases from NETs, with 71% sensitivity and 85-100% specificity.</s><s>This is higher than the commonly used T2 fast spin echo or dynamic gadolinium-enhanced MRI <ref type="bibr" target="#b89">[87]</ref> .</s><s>DWI, therefore, is currently the most promising technique for investigating NETs, usually in combination with 68 Ga-SSA-PET/CT <ref type="bibr" target="#b90">[88]</ref> .</s><s>Interestingly, the newly introduced hybrid technique PET/MRI has not yet resulted in an increased sensitivity compared to the stand-alone techniques <ref type="bibr" target="#b91">[89]</ref> .</s><s>DWI for oncologic imaging is based on the restricted diffusion of water molecules in highly cellular tissue such as tumors and has shown potential for distinguishing exocrine and endocrine pancreatic tumors <ref type="bibr" target="#b92">[90]</ref> and G1 from G2-G3 pancreatic neuroendocrine lesions by means of quantifying the tumor's apparent diffusion coefficient (ADC) in the images (ADC map) <ref type="bibr" target="#b93">[91]</ref> .</s><s>ADC has been shown to correlate with Ki67 <ref type="bibr" target="#b94">[92]</ref> .</s><s>To overcome the possible interference of tumor microcirculation in the measurements, an intravoxel incoherent motion model has been proposed to separate the true tissue diffusion; this results in a better characterization of pancreatic lesions <ref type="bibr" target="#b95">[93]</ref> .</s><s>Together with tumor size, the pure diffusion coefficient was able to differentiate G1 from G2 pancreatic NETs <ref type="bibr" target="#b96">[94]</ref> .</s></p><p><s>Dynamic Contrast-Enhanced Imaging Dynamic contrast-enhanced (DCE) imaging is applied to MRI, CT and US <ref type="bibr">[31,</ref><ref type="bibr" target="#b34">34,</ref><ref type="bibr" target="#b97">95]</ref> .</s><s>In contrast to PET/CT, it is not a whole-body technique, and the examination generally needs to be focused to include a limited axial field of view.</s><s>The technique requires substantial validation in consideration of the large intraindividual variability (20% for DCE MRI) and the lack of linear correlation between gadolinium concentrations in the tissue and the resulting signal intensity <ref type="bibr">[31,</ref><ref type="bibr" target="#b98">96]</ref> .</s><s>It has been recently demonstrated that perfusion parameters at DCE MRI have a definite pattern in malignant liver metastases.</s><s>The flow-related parameters, such as the arterial plasma flow and the arterial flow fraction, are both correlated with the mean SUV derived from 68 Ga-DOTATATE-PET (negatively) and 18 FDG-PET (positively).</s><s>This suggests that functional and molecular techniques evaluate different aspects of liver function and may offer complementary information <ref type="bibr" target="#b99">[97]</ref> .</s></p><p><s>DCE MRI parameters have also been used to monitor the response to PRRT <ref type="bibr" target="#b100">[98]</ref> .</s><s>Specific parameters related to perfusion and tissue exchange were spatially correlated with the heterogeneous uptake of 111 In-pentetreotide in a pancreatic NET model in rats <ref type="bibr" target="#b101">[99]</ref> .</s><s>Regions with high exchange-related parameters demonstrated high tracer uptake, and these parameters were better predictors of uptake as compared to parameters associated with the total amount of contrast.</s><s>Clinical confirmation of these observations would have important therapeutic and prognostic implications <ref type="bibr" target="#b101">[99]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional Imaging</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>64</head><p><s>Cu Labeling SSA labeled with 64 Cu is of interest due to the excellent image quality compared to conventional scintigraphy and the possibility of imaging at a later time compared to 68 Ga-SSA, thus matching more closely the kinetics of receptor uptake, namely 3 and 24 h after injection, due to the 12.5-hour half-life.</s><s>The latter allows for easy distribution to other diagnostic centers.</s><s>Drawbacks are the need for a cyclotron for its production and a higher radiation dose to the patient as compared to 68 Ga-SSA ( 68 Ga t 1/2 68 min).</s><s>Direct comparisons with 68 Ga-SSA-PET/CT are warranted <ref type="bibr" target="#b24">[24]</ref> .</s></p><p><s>Novel SSA Antagonists Besides radiolabeled SSA, the workhorse of nuclearmedicine NET imaging for 2 decades, alternative radiopharmaceuticals with an increased diagnostic accuracy <ref type="bibr" target="#b102">[100]</ref> have been identified and developed.</s><s>In this respect, the use of SSR antagonists represents a highly promising strategy <ref type="bibr" target="#b103">[101]</ref> .</s><s>The lack of internalization and the recognition of increased binding sites is an inversion of the current paradigm of agonist binding and is, therefore, of great interest to explore.</s><s>Paradoxically, antagonists result in a higher and longer retention in tumors and better imaging results <ref type="bibr" target="#b104">[102]</ref> .</s><s>In vitro, the 177 Lu-labeled compound DOTA-BASS binds to more receptor sites than the agonist DOTATATE, while, in vivo, the same peptide labeled with 111 In demonstrated a higher tumor uptake than 111 In-pentetreotide.</s><s>This implies a higher sensitivity compared to conventional scintigraphy and may translate, using the therapeutic counterpart, into a greater treatment benefit <ref type="bibr" target="#b104">[102,</ref><ref type="bibr" target="#b105">103]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GLP-1 Receptor Peptides</head><p><s>The development of novel receptor peptides that can identify a particular tumor or one with a specific secretory product needs to be investigated.</s><s>A number of peptides have been tested in preclinical and clinical trials.</s><s>Among these, GLP-1 receptor peptides, like 111 In-exendin-4 for the localization of occult insulinomas, are the most advanced for clinical application <ref type="bibr" target="#b106">[104]</ref> . 111</s><s>In-exendin-4 addresses the general paucity of SSRs in insulinoma.</s><s>GLP-R and SSR imaging, therefore, demonstrate the biologically mutable aspect of insulinomas, which may be GLP-R positive and SSR negative or vice versa, a reflec-tion of their malignant phenotype <ref type="bibr" target="#b107">[105]</ref> .</s><s>In this respect, <ref type="bibr" target="#b68">68</ref> Ga-exendin-4 has been recently tested for PET/CT imaging in clinical practice <ref type="bibr" target="#b108">[106,</ref><ref type="bibr" target="#b109">107]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Others</head><p><s>Other receptor peptides potentially of use in NET imaging include GRP receptor ligands, such as bombesin agonists and antagonists labeled with 99m Tc or with 68 Ga, and gastrin/cholecystokinin analogs, such as 111 In-labeled minigastrin.</s><s>The low plasma stability and high kidney retention, however, classically limited the diffusion of these peptides <ref type="bibr" target="#b102">[100]</ref> .</s><s>Nevertheless, newer, more stable molecules and the coadministration of specific enzyme inhibitors, such as the neutral endopeptidase inhibitor phosphoramidon, can be utilized to increase the bioavailability of these compounds <ref type="bibr" target="#b110">[108]</ref> .</s><s>Alternative strategies include the use of 89 Zr-labeled bevacizumab to evaluate NETs of different origins treated with everolimus.</s><s>A decrease in the SUV during treatment suggested that this technique could be an early predictor of the efficacy of antiangiogenesis treatments <ref type="bibr" target="#b111">[109]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integration of Biological Information to Amplify Accuracy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biological Indices</head><p><s>In order to advance NET diagnosis and better predict prognosis and optimize therapies, there is a need to integrate the biological information of tumor pathophysiology with anatomic and molecular diagnostic strategies.</s><s>Thus, the relationship between the intrinsic variability of individual NET cells (EC, β, ECL, D, Clara, etc.) that comprise the different tumor types and imaging strategies requires investigation.</s><s>This should include a delineation of histopathological indices, high-throughput molecular analyses, receptor subtyping and characterization as well as the determination of metabolic parameters that define function and proliferation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nomograms</head><p><s>It is clear that monoanalyte-derived information can never be as effective as the product of multianalyte parameters.</s><s>Thus, an image alone is, by definition, limited by the lack of additional, relevant parameters that can be integrated into an amplifiable diagnostic quotient.</s><s>Inclusion of such additional material, in a mathematical probability index, or in a matrix or via a nomogram, has proved of considerable added value in other disciplines <ref type="bibr" target="#b112">[110]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuroendocrine Tumor Imaging</head><p><s>Neuroendocrinology 2015;101:1-17 DOI: 10.1159/000367850 <ref type="bibr" target="#b12">13</ref> Recently, various studies have explored the combination of the information deriving from imaging with clinical and biologic data, in order to obtain predictive algorithms that are able to confer a higher accuracy to diagnostic techniques.</s><s>As an example, a combination of morphologic information, such as tumor size &gt;4 cm and presence of lymph nodes when combined with biological information, such as the tumor grade, has been utilized in a model, deriving from the multiple logistic regression of a retrospective series, that is able to predict the preoperative risk of lymph node metastasis in nonfunctioning pancreatic NETs <ref type="bibr" target="#b113">[111]</ref> .</s></p><p><s>A more detailed nomogram was constructed to determine prognosis of small intestine NETs.</s><s>This utilized 15 clinical and biological variables, such as age, symptoms, 5-HIAA, CgA, tumor size, invasion, metastasis, histology, Ki67 index and adopted therapy.</s><s>The resulting score was able to identify significant differences in survival, thus demonstrating that a multilevel parallel assessment of different forms of tumor-/patient-relevant information may be an appropriate tool that can strengthen both diagnostic and prognostic accuracy <ref type="bibr" target="#b112">[110]</ref> .</s></p><p><s>Recently, a mathematical model incorporating proliferation, infiltration, metabolism and mass effect has been proposed to estimate the tumor growth in pancreatic NETs.</s><s>This includes integration of the theoretical equations with the observations derived from dual-phase con-trast-enhanced CT and FDG-PET.</s><s>However, in the absence of tumors' inherent biological parameters, the model only reflected a current situation and could not predict future progression <ref type="bibr" target="#b114">[112]</ref> .</s></p><p><s>To amplify information provided by NET imaging techniques, the integration of tumor features and bloodbased biomarkers into prognostic nomograms may be useful.</s><s>An informative source of information would be the integration of tumor data, such as circulating tumor cells and relevant genes, detected through mRNA measurement or circulating autoantibodies, with imaging <ref type="bibr" target="#b115">[113]</ref> .</s><s>In particular, circulating genomic data obtained from blood (tumor transcript profile or signature) at the time of imaging could be combined with morphologic or functional tumor characteristics and, thus, allow for the development of a personalized predictive assessment of tumor status before, during and after treatment <ref type="bibr" target="#b2">[3]</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Coda</head><p><s>Diagnostic imaging has substantially advanced in the past 40 years ( fig. <ref type="figure" target="#fig_6">3</ref> ).</s><s>This development has been facilitated by the collaboration between medicine professionals and industrial partners.</s><s>It is evident that progress occurs through team-based science, and future multidisciplinary teams in our hospitals need not only include  111 In-pentetreotide 68 Ga-DOTA-peptide PET 18 F-FDG PET of NETs medicine professionals but also experts on genomics, laboratory medicine and epidemiology.</s><s>Given the complexity of the carcinogenic process, the intrinsic heterogeneity of cancer and tumor microenvironment, it is unlikely that any single diagnostic test will be effective.</s><s>Rather, NET diagnosis will be a process utilizing a variety of methods including genomics-epigenomics-proteomics on biosamples such as blood, urine and tumor tissue in combination with anatomical and molecular imaging (hybrid imaging) for localization, delineation and staging of the disease, as the basis for optimal selection of therapy.</s></p><p><s>Future advances in NET diagnosis need to consider two realities.</s><s>Firstly, a short-term accelerated strategy to focus upon validation of the present techniques or sequences of techniques.</s><s>The second is a long-term strategy, to develop a more comprehensive multilevel integration of biologic and genomic information to provide added value to the imaging techniques.</s><s>This will aim at facilitating recognition of the complete status of an individual tumor.</s><s>Thus, a fusion product of molecular and genomic information with tumor imaging is likely to be the quintessence of future NET diagnosis and define the progress from darkness to light.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig.2.</s><s>Methods for the identification of primary and metastatic gastroenteropancreatic NETs.</s><s>Data are pooled from 52 studies and are mean (95% confidence interval).</s><s>Data for specificity and sensitivity are not comparable across studies.</s><s>S = Calculated sensitivity.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Neuroendocrinology 2015;101:1-17 DOI: 10.1159/000367850 5</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>111</head><label>111</label><figDesc><div><p></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>. The intrinsic multiplanarity of the PET techniques and the coregistration with high-resolution Neuroendocrine Tumor Imaging Neuroendocrinology 2015;101:1-17 DOI: 10.1159/000367850 7</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Time line of imaging development in NETs. 131</s><s>I-MIBG = 131 I-metaiodobenzylguanidine; 11 C-HTP = 11 C-hydroxytryptophan.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>The role of morphologic and molecular imaging techniques in NETs</s></p></div></figDesc><table><row><cell></cell><cell>Primary</cell><cell>Localization</cell><cell>Staging</cell><cell>Restaging</cell><cell>Therapy selection</cell><cell>Modification of</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>management</cell></row><row><cell>GEP</cell><cell>Pancreas</cell><cell>SRI [21, 47, 114, 115]</cell><cell>SRI + CT/MRI [5, 6]</cell><cell>SRI + CT/MRI [5, 6]</cell><cell></cell></row><row><cell></cell><cell>(functional) a</cell><cell>EUS [1, 8]</cell><cell>11 C-5-HTP [26]</cell><cell>11 C-5-HTP [26]</cell><cell></cell></row><row><cell></cell><cell></cell><cell>CT/MRI [8, 116]</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>11 C-5-HTP [26]</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Strengths of anatomic (a) and molecular imaging (b) techniques</s></p></div></figDesc><table><row><cell cols="2">a Anatomic imaging</cell><cell></cell><cell></cell></row><row><cell></cell><cell>MDCT</cell><cell>MRI</cell><cell>US techniques</cell></row><row><cell>Technical</cell><cell cols="2">High spatial resolution (2-4 mm or below) High spatial resolution (2-4 mm)</cell><cell>Absence of radiation exposure</cell></row><row><cell>points</cell><cell>Multiplanar imaging</cell><cell>High soft-tissue contrast</cell><cell></cell></row><row><cell></cell><cell>Volume rendering</cell><cell>Multiplanar imaging</cell><cell></cell></row><row><cell></cell><cell>High sensitivity for small-bowel lesions</cell><cell>Volume rendering</cell><cell></cell></row><row><cell></cell><cell>(CT enterography)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Absence of radiation exposure</cell><cell></cell></row><row><cell>Clinical</cell><cell>Initial assessment, localization, staging,</cell><cell>Localization, staging, restaging,</cell><cell>Abdominal US: biopsy guidance</cell></row><row><cell>points</cell><cell>restaging and definition of margins for</cell><cell>definition of margins for operability</cell><cell>for liver/abdominal lesions</cell></row><row><cell></cell><cell>operability</cell><cell>and problem-solving technique</cell><cell></cell></row><row><cell></cell><cell>High sensitivity for pulmonary, hepatic</cell><cell>High sensitivity for pancreatic and</cell><cell>CEUS: possible characterization</cell></row><row><cell></cell><cell>and brain lesions</cell><cell>hepatic lesions</cell><cell>of dubious lesions at CT/MRI</cell></row><row><cell></cell><cell>Availability, rapidity and reproducibility</cell><cell>Reproducibility</cell><cell>EUS: high sensitivity for pancreatic</cell></row><row><cell></cell><cell></cell><cell></cell><cell>NETs, guidance for biopsy</cell></row><row><cell></cell><cell>Independency of body habitus and extent</cell><cell>Visualization of the biliary and pancreatic</cell><cell></cell></row><row><cell></cell><cell>of disease</cell><cell>ducts (cholangiopancreatic MRI)</cell><cell></cell></row></table><note><p><s>IOUS: delineation of liver and pancreatic lesions before resection Biopsy guidance for thoracic lesions Use of organ-specific contrast media b Molecular imaging</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Limitations of anatomic (a) and molecular imaging (b) techniques</s></p></div></figDesc><table><row><cell cols="2">a Anatomic imaging</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>MDCT</cell><cell></cell><cell>MRI</cell><cell></cell><cell>US techniques</cell></row><row><cell>Technical</cell><cell>Radiation exposure</cell><cell></cell><cell>Cost</cell><cell></cell><cell cols="2">US techniques: operator dependency</cell></row><row><cell>points</cell><cell cols="2">Use of iodinated contrast media may cause</cell><cell>Lack of wide availability</cell><cell></cell><cell cols="2">EUS: specialized expertise</cell></row><row><cell></cell><cell cols="2">renal impairment and other adverse effects</cell><cell></cell><cell></cell><cell cols="2">required, lack of wide availability</cell></row><row><cell></cell><cell cols="2">Strict dependency on the exact contrast</cell><cell cols="2">Long examination procedure</cell><cell cols="2">IOUS: operator dependency</cell></row><row><cell></cell><cell cols="2">phase and dosage for comparability of</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">especially hypervascular lesions</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Clinical</cell><cell cols="2">Difficult (re)assessment of small-volume</cell><cell cols="2">Extensive patient cooperation</cell><cell cols="2">Abdominal US and CEUS: low</cell></row><row><cell>points</cell><cell cols="2">disease (e.g. small lymph nodes)</cell><cell>required</cell><cell></cell><cell cols="2">sensitivity for GEP NETs,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">suboptimal assessment of pancreas</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">and retroperitoneal lesions due to</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">overlying abdominal structures</cell></row><row><cell></cell><cell cols="2">Difficult (re)assessment of large-volume</cell><cell>Difficult (re)assessment of</cell><cell></cell><cell cols="2">Difficult (re)assessment of</cell></row><row><cell></cell><cell>disease (coalescence)</cell><cell></cell><cell cols="2">small-volume disease (e.g. small</cell><cell cols="2">large-volume disease, especially in</cell></row><row><cell></cell><cell></cell><cell></cell><cell>lymph nodes)</cell><cell></cell><cell cols="2">the liver (poor demarcation,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>coalescence)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Difficult assessment of small</cell><cell></cell><cell cols="2">Thorax cannot be examined</cell></row><row><cell></cell><cell></cell><cell></cell><cell>thoracic lesions</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Difficulty in capturing modifications in</cell><cell>Difficult (re)assessment of</cell><cell></cell><cell></cell></row><row><cell></cell><cell>slow-growing tumors</cell><cell></cell><cell>large-volume disease (poor</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>demarcation, coalescence)</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Difficulty in defining response (e.g. RECIST)</cell><cell>Difficulty in capturing</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">if necrosis/fibrosis/hemorrhage occurs</cell><cell cols="2">modifications in slow-growing</cell><cell></cell></row><row><cell></cell><cell cols="2">without a marked decrease in tumor size</cell><cell>tumors</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Difficulty in defining response</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(e.g. RECIST) if necrosis/</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>fibrosis/hemorrhage occurs</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">without a marked decrease in</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>tumor size</cell><cell></cell><cell></cell></row><row><cell cols="2">b Molecular imaging</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>111 In-pentetreotide</cell><cell>68 Ga-PET</cell><cell>18 F-DOPA</cell><cell cols="2">11 C-5-HTP</cell><cell>18 FDG</cell></row><row><cell>Technical</cell><cell>Radiation exposure</cell><cell>Radiation exposure</cell><cell>Radiation exposure</cell><cell cols="2">Radiation exposure</cell><cell>Radiation exposure</cell></row><row><cell>points</cell><cell cols="5">Low spatial resolution Lack of full validation Lack of full validation Lack of full validation</cell></row><row><cell></cell><cell>Long procedure</cell><cell>Lack of registration</cell><cell></cell><cell cols="2">Lack of registration</cell></row><row><cell></cell><cell>(2-4 days)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Clinical</cell><cell>Low sensitivity for</cell><cell>Possible interference</cell><cell>Lack of therapeutic</cell><cell cols="2">Available only in</cell><cell>Not validated for</cell></row><row><cell>points</cell><cell>insulinomas</cell><cell>from cold analogues</cell><cell>indications</cell><cell cols="2">specialized centers</cell><cell>prognostication on</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>large series</cell></row><row><cell></cell><cell>Possible interference</cell><cell></cell><cell>Sensitivity seems</cell><cell cols="2">Lack of therapeutic</cell></row><row><cell></cell><cell>from cold analogues</cell><cell></cell><cell>inferior to receptor</cell><cell cols="2">indications</cell></row><row><cell></cell><cell></cell><cell></cell><cell>PET</cell><cell></cell><cell></cell></row><row><cell cols="2">GEP = Gastroenteropancreatic.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Opportunities for anatomic and molecular imaging techniques</s></p></div></figDesc><table><row><cell></cell><cell>Advance in current techniques</cell><cell>Novel techniques and strategies</cell></row><row><cell>Anatomic imaging</cell><cell>Validation of Choi criteria for CT-based</cell><cell>DWI techniques (ADC maps, pure diffusion</cell></row><row><cell></cell><cell>therapy monitoring</cell><cell>parameters)</cell></row><row><cell></cell><cell>Integration of molecular imaging in RECIST</cell><cell>DCE protocols for MRI, CT and US</cell></row><row><cell></cell><cell>criteria (e.g. PERCIST) for therapy monitoring</cell><cell></cell></row><row><cell></cell><cell>Integration of functional MRI parameters in</cell><cell></cell></row><row><cell></cell><cell>RECIST criteria (e.g. vascularization, necrosis)</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Neuroendocrinology 2015;101:1-17 DOI: 10.1159/000367850</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Gastroenteropancreatic neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Chung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="61" to="72" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Biomarkers in neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Duque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gupta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JOP</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="372" to="376" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drozdov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">63364</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Gastrointestinal carcinoids: the evolution of diagnostic strategies</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Latich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zikusoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="572" to="582" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: an analysis in 188 patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gotthardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Dirkmorfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">U</forename><surname>Wied</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Digestion</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="80" to="85" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinics (Sao Paulo)</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="109" to="112" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Best Pract Res Clin Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="803" to="818" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Vullierme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kaltsas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="167" to="183" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ichikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Federle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">216</biblScope>
			<biblScope unit="page" from="163" to="171" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Rappeport</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kjaer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Radiol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="248" to="256" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Sahani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Bonaffini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fernandez-Del</forename><surname>Castillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">266</biblScope>
			<biblScope unit="page" from="38" to="61" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Khashab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yong</forename><forename type="middle">E</forename><surname>Lennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastrointest Endosc</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="691" to="696" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Johanssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boivin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lochs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastrointest Endosc</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="660" to="665" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Value of CT enteroclysis in suspected small-bowel carcinoid tumors</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kamaoui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>De-Luca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ficarelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="629" to="633" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">MR enteroclysis in the diagnosis of small-bowel neoplasms</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Van Weyenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Meijerink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jacobs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="page" from="765" to="773" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Small-bowel neoplasms: prospective evaluation of MR enteroclysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Masselli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Polettini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Casciani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">251</biblScope>
			<biblScope unit="page" from="743" to="750" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">SPECT/CT hybrid imaging with 111 In-pentetreotide in assessment of neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Krausz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Keidar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kogan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Endocrinol (Oxf)</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="565" to="573" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Teunissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Valkema</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="S27" to="S51" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Borner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1751" to="1757" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Radiolabelled peptides in diagnosis and therapy: an introduction</title>
		<author>
			<persName><forename type="first">A</forename><surname>Al-Nahhas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fanti</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S1" to="S3" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Decristoforo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kendler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="508" to="518" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">68 Ga-labelled peptides for diagnosis of gastroenteropancreatic NET</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Campana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tomassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fanti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S52" to="S60" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The role of 68 Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111 In-DTPA-octreotide scintigraphy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Srirajaskanthan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kayani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Quigley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="875" to="882" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Clinical PET of neuroendocrine tumors using 64 Cu-DOTATATE: first-in-humans study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pfeifer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Knigge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mortensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1207" to="1215" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">6-L -18 F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chirakal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Marriott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="573" to="586" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Wholebody 11 C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography</title>
		<author>
			<persName><forename type="first">H</forename><surname>Orlefors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Garske</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="3392" to="3400" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Functional imaging of neuroendocrine tumors: a headto-head comparison of somatostatin receptor scintigraphy, 123 I-MIBG scintigraphy, and 18 F-FDG PET</title>
		<author>
			<persName><forename type="first">T</forename><surname>Binderup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Knigge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loft</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="704" to="712" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Role of 18 FDG PET/CT in patients treated with 177 Lu-DOTATATE for advanced differentiated neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">S</forename><surname>Severi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Nanni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="881" to="888" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">18 F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">T</forename><surname>Binderup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Knigge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loft</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="978" to="985" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18 F-FDG PET: feasibility of a metabolic grading system</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ezziddin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sabet</surname></persName>
		</author>
		<idno type="DOI">10.1159/000367850</idno>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1" to="17" />
			<date type="published" when="2014">2014. 2015</date>
		</imprint>
	</monogr>
	<note>J Nucl Med</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rockall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="261" to="271" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Imaging features of carcinoid tumors of the gastrointestinal tract</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ganeshan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bhosale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">201</biblScope>
			<biblScope unit="page" from="773" to="786" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Diagnosis and prediction of neuroendocrine liver metastases: a protocol of six systematic reviews</title>
		<author>
			<persName><forename type="first">S</forename><surname>Arigoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ignjatovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sager</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JMIR Res Protoc</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e60</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art</title>
		<author>
			<persName><forename type="first">L</forename><surname>De Mestier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dromain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Assignies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="R105" to="R120" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Krajewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nishino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">201</biblScope>
			<biblScope unit="page" from="811" to="824" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Liver MRI at 3.0 tesla: comparison of image quality and lesion detectability between single-source conventional and dual-source parallel radiofrequency transmissions</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Comput Assist Tomogr</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="546" to="553" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dromain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>De Baere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lumbroso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="70" to="78" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Staging of neuroendocrine tumours: comparison of [ 68 Ga]DOTATOC multiphase PET/ CT and whole-body MRI</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schraml</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Schwenzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Sperling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Imaging</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="63" to="72" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Contrast agents for hepatic MRI</title>
		<author>
			<persName><forename type="first">G</forename><surname>Morana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Salviato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guarise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Imaging</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="S24" to="S27" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dromain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>De Baere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="page" from="121" to="128" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">MRI of the pancreas: tumours and tumour-simulating processes</title>
		<author>
			<persName><forename type="first">W</forename><surname>Schima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Imaging</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="199" to="203" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Imaging of neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiol Clin North Am</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="529" to="548" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Gastrointestinal carcinoid tumors</title>
		<author>
			<persName><forename type="first">I</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Advances in Digestive Disease. Bethesda</title>
				<editor>
			<persName><forename type="first">C</forename><surname>Howden</surname></persName>
		</editor>
		<imprint>
			<publisher>AGA Institute Press</publisher>
			<date type="published" when="2007">2007</date>
			<biblScope unit="page" from="203" to="218" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Puli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kalva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Bechtold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="3678" to="3684" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Fine needle aspiration diagnosis of neuroendocrine tumors in the liver</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Naran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lallu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pathology</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="16" to="20" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Reply to comment on Pepe et al: Somatostatin receptor SPECT</title>
		<author>
			<persName><forename type="first">G</forename><surname>Pepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chiti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">302</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors</title>
		<author>
			<persName><forename type="first">R</forename><surname>Lebtahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cadiot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sarda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="853" to="858" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Kam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Essen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr Relat Cancer</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="R53" to="R73" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management</title>
		<author>
			<persName><forename type="first">B</forename><surname>Termanini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gibril</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Reynolds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="335" to="347" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d&apos;Etude du Syndrome de Zollinger-Ellison (GRESZE)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Cadiot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bonnaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lebtahi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="107" to="114" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">68 Ga-DOTA-peptides in the diagnosis of NET</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fanti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PET Clinics</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="37" to="42" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Imaging and PET/CT evaluation of GI tract cancers (in French)</title>
		<author>
			<persName><forename type="first">V</forename><surname>Laurent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Olivier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Radiol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="436" to="437" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Feasibility and availability of 68 Ga-labelled peptides</title>
		<author>
			<persName><forename type="first">C</forename><surname>Decristoforo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Pickett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Verbruggen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="S31" to="S40" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Comparison between 68 Ga-DOTA-NOC and 18 F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tomassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Castellucci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1431" to="1438" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Intraindividual comparison of 68 Ga-DOTA-TATE and 18 F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">A</forename><surname>Haug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Auernhammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wangler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="765" to="770" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Standardized uptake values of 68 Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Campana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pezzilli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="353" to="359" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">68 Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Campana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="669" to="673" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Improved staging of patients with carcinoid and islet cell tumors with 18 F-dihydroxy-phenylalanine and 11 C-5-hydroxy-tryptophan positron emission tomography</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Koopmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">C</forename><surname>Neels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">P</forename><surname>Kema</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1489" to="1495" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">18 F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Imperiale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gabriel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="367" to="372" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">C</forename><surname>Toumpanakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rinke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">21</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Castano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Maecke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Metastasis Rev</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Lanreotide in metastatic enteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Caplin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Cwikla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="224" to="233" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [ 177 Lu-DOTA0, Tyr3]octreotate</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Van Vliet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Teunissen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1689" to="1696" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">MRI of pulmonary nodules</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kurihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Matsuoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamashiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="W210" to="W216" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Imaging of gastroenteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="28" to="43" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">111 In-pentetreotide scintigraphy: procedure guidelines for tumour imaging</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bombardieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Aktolun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1441" to="1448" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE</title>
		<author>
			<persName><forename type="first">I</forename><surname>Virgolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bomanji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2004" to="2010" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Molecular imaging with 68 Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kaemmerer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Peter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lupp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1659" to="1668" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">18 F-DOPA and other radiopharmaceuticals for imaging unknown primary neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">O</forename><surname>Schillaci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="357" to="359" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria</title>
		<author>
			<persName><forename type="first">H</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Charnsangavej</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Faria</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1753" to="1759" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Hobbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Chandler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="758" to="767" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">T</forename><surname>Denecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Baur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ihm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Radiol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="e550" to="e555" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases?</title>
		<author>
			<persName><forename type="first">F</forename><surname>Ceelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Theisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">G</forename><surname>De Albeniz</surname></persName>
		</author>
		<idno type="DOI">10.1159/000367850</idno>
	</analytic>
	<monogr>
		<title level="j">J Magn Reson Imaging</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1" to="17" />
			<date type="published" when="2014">2014. 2015</date>
		</imprint>
	</monogr>
	<note>Neuroendocrinology</note>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Haug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Auernhammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wangler</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">68</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">CT for the early prediction of response to somatostatin receptormediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">-Dotatate</forename><surname>Ga</surname></persName>
		</author>
		<author>
			<persName><surname>Pet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1349" to="1356" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Wahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jacene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kasamon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="122S" to="150S" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">68 Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptormediated radionuclide therapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oberauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dobrozemsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1427" to="1434" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">In vivo binding of [ 68 Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumoursimpact of peptide mass</title>
		<author>
			<persName><forename type="first">I</forename><surname>Velikyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Eriksson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucl Med Biol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="265" to="275" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Quantitative and qualitative intrapatient comparison of 68 Ga-DOTATOC and 68 Ga-DOTATATE: net uptake rate for accurate quantification</title>
		<author>
			<persName><forename type="first">I</forename><surname>Velikyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sorensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="204" to="210" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Bone metastases in patients with neuroendocrine tumor: 68 Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Putzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Henninger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1214" to="1221" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Rare metastases detected by 68 Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">C</forename><surname>Carreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Baum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Recent Results Cancer Res</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="379" to="384" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">68 Ga-DOTATOC versus 68 Ga-DOTATATE PET/ CT in functional imaging of neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Poeppel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Binse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Petersenn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1864" to="1870" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title level="m" type="main">Comparison of 68 Ga-DOTATATE and 68 Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">L</forename><surname>Kabasakal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Demirci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ocak</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1271" to="1277" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Does PRRT with standard activities of 177 Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sabet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nagarajah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Dogan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EJNMMI Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">82</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Comparison of 68 Ga-DOTATOC biodistribution in patients with and without splenectomy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kratochwil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mavriopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rath</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Q J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Predictive value of 18 F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors</title>
		<author>
			<persName><forename type="first">E</forename><surname>Garin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Jeune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Devillers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="858" to="864" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy -the Bad Berka experience</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Kulkarni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Theranostics</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="437" to="447" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging</title>
		<author>
			<persName><forename type="first">G</forename><surname>Assignies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bruno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Multimodal imaging for early functional response assessment of Y-/Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and Ga-DOTATOC-PET/CT</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wulfert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kratochwil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Choyke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Imaging Biol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Gadoxetate-enhanced versus diffusionweighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Mayerhoefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ba-Ssalamah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Radiol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1978" to="1985" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Diffusion-weighted magnetic resonance imaging of the pancreas: diagnostic benefit from an intravoxel incoherent motion model-based 3 b-value analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Concia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Sprinkart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Penner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Invest Radiol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="93" to="100" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">The value of gadoxetic acid-enhanced and diffusionweighted MRI for prediction of grading of pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Radiol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="140" to="148" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">E</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Yaghmai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Magn Reson Imaging</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1071" to="1079" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Intravoxel incoherent motion diffusion-weighted MR imaging for characterization of focal pancreatic lesions</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Yoon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="444" to="453" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Yoon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Invest Radiol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="396" to="402" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrastenhanced magnetic resonance imaging with tissue hypoxia markers and clinical response</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Yopp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kemeny</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2192" to="2199" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Raunig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="W134" to="W140" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography</title>
		<author>
			<persName><forename type="first">M</forename><surname>Armbruster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sourbron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haug</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Invest Radiol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="7" to="14" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response</title>
		<author>
			<persName><forename type="first">K</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Orton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Davidson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">263</biblScope>
			<biblScope unit="page" from="139" to="148" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Can DCE-MRI explain the heterogeneity in radiopeptide uptake imaged by SPECT in a pancreatic neuroendocrine tumor model?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Haeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Groen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e77076</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Radiopeptide imaging and therapy in Europe</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fanti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="42S" to="55S" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ginj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Waser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="16436" to="16441" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">First clinical evidence that imaging with somatostatin receptor antagonists is feasible</title>
		<author>
			<persName><forename type="first">D</forename><surname>Wild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Behe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1412" to="1417" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Evaluation of 177 Lu-DOTA-sst2 antagonist versus 177 Lu-DOTA-sst2 agonist binding in human cancers in vitro</title>
		<author>
			<persName><forename type="first">R</forename><surname>Cescato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Waser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1886" to="1890" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Glucagonlike peptide 1-receptor scans to localize occult insulinomas</title>
		<author>
			<persName><forename type="first">D</forename><surname>Wild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Macke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Christ</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="766" to="768" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas</title>
		<author>
			<persName><forename type="first">D</forename><surname>Wild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Christ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Caplin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1073" to="1078" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68 Ga-labeled DO3A-exendin-4</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Selvaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Velikyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Johansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1458" to="1463" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Detection of metastatic insulinoma by positron emission tomography with [ 68 Ga]exendin-4-a case report</title>
		<author>
			<persName><forename type="first">O</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Velikyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Selvaraju</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="1519" to="1524" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">To serve and protect&apos;: enzyme inhibitors as radiopeptide escorts promote tumor targeting</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Nock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Maina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="121" to="127" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Everolimus reduces 89 Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Van Asselt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Oosting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Brouwers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">A nomogram to assess small-intestinal neuroendocrine tumor (&apos;carcinoid&apos;) survival</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="143" to="157" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-Pan-NETs)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Partelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gaujoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boninsegna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Surg</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="932" to="939" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Patient specific tumor growth prediction using multimodal images</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Sadowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Weisbrod</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Image Anal</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="555" to="566" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science</title>
		<author>
			<persName><forename type="first">V</forename><surname>Giandomenico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ponten</surname></persName>
		</author>
		<idno type="DOI">10.1159/000367850</idno>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1" to="17" />
			<date type="published" when="2013">2013. 2015</date>
		</imprint>
	</monogr>
	<note>Neuroendocrinology</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gibril</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Doppman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="26" to="34" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Oei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Dop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Reubi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Lamberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">733</biblScope>
			<biblScope unit="page" from="416" to="424" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Tkacz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hammond</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jpn J Radiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="85" to="91" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours</title>
		<author>
			<persName><forename type="first">A</forename><surname>Chiti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Savelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Romeo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bellanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rodari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Van Graafeiland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Monetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bombardieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1396" to="1403" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Somatostatin analogue scintigraphy in carcinoid tumours</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kwekkeboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Oei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Kooij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Lamberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="283" to="292" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Kälkner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Janson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Westlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="5801S" to="5804S" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumors of the diffuse neuroendocrine system</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Current status of gastrointestinal carcinoids</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Latich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1717" to="1751" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Kooij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Breeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Oei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Reubi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bruns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kwekkeboom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="652" to="658" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">North American Neuroendocrine Tumor Society (NANETS): NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Harrison</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Strosberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Krenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Woltering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Maples</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pancreas</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="784" to="798" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">A comparison of 68 Ga-DOTATATE and 18 F-FDG PET/CT in pulmonary neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kayani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Conry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Groves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1927" to="1932" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">V</forename><surname>Ambrosini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Campana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nanni</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">68</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?</title>
		<author>
			<persName><forename type="first">-Dota-Noc</forename><surname>Ga</surname></persName>
		</author>
		<author>
			<persName><surname>Pet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1278" to="1283" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
